[195 Pages Report] The Antimicrobial Susceptibility Testing Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.02 billion in 2024, at a CAGR 5.83% to reach USD 5.67 billion by 2030.
Antimicrobial susceptibility testing (AST) determines the effectiveness of antibiotics or other antimicrobial drugs against microorganisms such as bacteria, fungi, and viruses. This testing method is an essential tool for guiding the selection of appropriate antibiotics used in treating infectious diseases and monitoring the emergence of drug-resistant strains of microorganisms. The market is experiencing growth due to various factors, including the rising incidence of infectious disorders, the growing adoption of point-of-care testing facilities, and the surging demand for prompt and precise detection of antibiotic resistance. However, challenges affecting the expansion of the AST market comprise high costs associated with advanced technologies such as molecular diagnostics instruments or automated systems, limiting their adoption by small-scale laboratories. In addition, limited access to robust healthcare infrastructure in developing countries, insufficient funding for research and development (R&D), lack of skilled professionals in the field, and variation in regulatory policies among different regions affecting market entry or expansion efforts are the additional obstacles affecting the expansion of the market. Additionally building partnerships between industry stakeholders such as diagnostic manufacturers, healthcare providers researchers and pharmaceutical companies can streamline processes while driving advancements in AST technologies. Moreover, the increasing demand for accurate and timely diagnosis of infectious diseases is expected to create lucrative opportunities for the market, particularly with the technological advancement in disease diagnosis testing techniques and the introduction of new genomic identification methods.
The Americas and Europe are significant regions in the global antimicrobial susceptibility testing market due to the rise in infectious diseases and advanced healthcare infrastructure. The Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN), which tracks antimicrobial resistance patterns in nationwide healthcare facilities, promotes AST adoption while ensuring high-quality data collection. In Latin America, significant progress is observed in the field of antimicrobial susceptibility testing (AST), with countries such as Brazil adopting and executing guidelines established by the Clinical & Laboratory Standards Institute (CLSI). This crucial development contributes to the global efforts in combating antimicrobial resistance, thereby ensuring effective treatment options for bacterial infections. Furthermore, the European Centre for Disease Prevention and Control (ECDC) plays a pivotal role in tracking resistance patterns across Europe through its European Antimicrobial Resistance Surveillance Network (EARS-Net). The Asia-Pacific (APAC) is expected to experience substantial growth in the market due to rising awareness about infectious diseases, increasing healthcare expenditure, and emerging drug-resistant microorganisms. China, Japan, and India are the major markets for antimicrobial susceptibility testing within the Asia-Pacific. These nations have a high burden of infectious diseases and a large population, which is expected to drive the demand for AST products and services. Moreover, government initiatives worldwide to control infectious diseases and rising investments & funding in healthcare infrastructure are expected to bolster the market growth in the APAC.
Automated products use various methods such as fluorescence, spectrophotometry, and automated imaging to detect microbial growth and identify the susceptibility of microorganisms to different antibiotics. Manual products include various consumables, such as minimum inhibitory concentration (MIC) strips, susceptibility discs, and susceptibility plates. Manual products are widely used in healthcare facilities, particularly in resource-limited settings where automated systems are not available or cost-effective. Manual testing methods produce accurate results and are an important tool in diagnosing and treating infectious diseases. However, these testing methods are more time-consuming and subjective compared to automated systems.
The disk diffusion method involves placing antibiotic disks onto agar plates inoculated with microorganism testing. The plates are incubated, and the absence or presence of an inhibition zone around the disk is utilized to define the susceptibility or resistance of the microorganism to the antibiotic. The Epsilometer test (ETEST) method involves using a plastic strip containing a gradient of antibiotic concentrations. The minimum inhibitory concentration (MIC) after incubation of the antibiotic is determined by locating the point where the ellipse intersects the strip. Rapid automation method systems use various techniques, including optical detection and impedance measurement, to provide accurate and timely results.
Antimicrobial susceptibility testing is vital in determining effective treatments for microbial infections that focus on antibacterial, antifungal, and antiparasitic susceptibility testing. Antibacterial susceptibility testing is crucial in managing bacterial infections by identifying suitable antibiotics against specific bacterial strains. Additionally, antifungal susceptibility testing guides treatment for fungal infections caused by Candida, Aspergillus, and other pathogenic fungi. Moreover, antiparasitic susceptibility testing determines the effectiveness of antiparasitic drugs against infections caused by parasites such as Plasmodium (malaria), Leishmania, and Trypanosoma species.
AST is widely used in clinical diagnostics to determine the appropriate antibiotic treatment for patients and to identify the effectiveness of antibiotics against a specific microorganism. These diagnostics decrease the risk of treatment failure, reduce the duration of hospitalization, and minimize the development of antibiotic resistance. Moreover, AST is used to evaluate the efficacy of new antibiotics and determine the minimum inhibitory concentration (MIC) of new drugs. In context, this information is valuable in determining the appropriate dosage of the drug and the potential for developing antibiotic resistance.
Hospitals and diagnostic laboratories use antimicrobial susceptibility testing to diagnose and select treatments accurately. Hospitals and diagnostic laboratories perform antimicrobial testing on various sample types, including blood, urine, and sputum. Pharmaceutical and biotechnology companies use antimicrobial susceptibility testing for drug development processes, as it helps to identify promising candidates for further study.
The market dynamics represent an ever-changing landscape of the Antimicrobial Susceptibility Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Antimicrobial Susceptibility Testing Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Antimicrobial Susceptibility Testing Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Antimicrobial Susceptibility Testing Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Antimicrobial Susceptibility Testing Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Antimicrobial Susceptibility Testing Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Antimicrobial Susceptibility Testing Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Antimicrobial Susceptibility Testing Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Antimicrobial Susceptibility Testing Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Antimicrobial Susceptibility Testing Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Antimicrobial Susceptibility Testing Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antimicrobial Susceptibility Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antimicrobial Susceptibility Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Strathclyde spin-out Microplate dx secures GBP 2.5 million in funding
Microplate Dx raised GBP 2.5 million (USD 3.11 million) in seed funding to advance the development of its innovative point-of-care diagnostic platform. The technology aims to quickly detect bacterial infections and guide physicians toward the most effective treatment options by rapidly identifying suitable antibiotics while avoiding ineffective ones. The platform merges novel hardware components with proprietary data processing algorithms to perform quick antibiotic susceptibility tests. [Published On: 2023-09-11]
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics has introduced its antimicrobial susceptibility testing (AST) services, aiming to support biotechnology and pharmaceutical researchers in detecting the sensitivity of test bacteria to antimicrobial drugs. The new AST services provide valuable insights into antibiotic treatment options and can be seamlessly integrated into Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) environments, ensuring full traceability. [Published On: 2023-07-19]
Sysmex Launches World's First Point-of-Care Testing System in Europe to Detect Antimicrobial Susceptibility in Just 30 Minutes
Sysmex Corporation introduced a point-of-care testing system for detecting antimicrobial susceptibility in Europe. The innovative system aims to expedite the diagnosis and treatment of urinary tract infections (UTIs) by using patient urine samples to detect bacterial presence and evaluate antimicrobial effectiveness. This rapid detection promotes the proper use of antimicrobials in primary care settings and contributes to combating antimicrobial resistance (AMR), a global challenge necessitating collaborative efforts. [Published On: 2023-06-26]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antimicrobial Susceptibility Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Accelerate Diagnostics, Inc., Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE Tıbbi Malz. San. ve Tic. Ltd. Sti., BioMérieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, Danaher Corporation, ELITech Group SAS, Erba Lachema s.r.o., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Leading Biology, Inc., Liofilchem S.r.l., Mast Group Ltd., MP Biomedicals, LLC, Pfizer Inc., Qiagen N.V., QuantaMatrix Inc., Rapid Test Methods Ltd., Resistell AG, Synoptics Group, Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..
This research report categorizes the Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product Type
- Automated Products
- Consumables
- Manual Products
- Minimum Inhibitory Concentration (MIC) Strips
- Susceptibility Discs
- Susceptibility Plates
- Method
- Agar Dilution
- Disks Diffusion
- ETEST
- Genotyping Methods
- Rapid Automation Method
- Type
- Antibacterial Susceptibility Testing
- Antifungal Susceptibility Testing
- Antiparasitic Susceptibility Testing
- Application
- Clinical Diagnostics
- Drug Discovery & Development
- Epidemiology
- End-User
- Contract Research Organizations
- Hospital & Diagnostic Centers
- Pharmaceutical & Biotechnology
- Research & Academic Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Antimicrobial Susceptibility Testing Market, by Product Type
- Antimicrobial Susceptibility Testing Market, by Method
- Antimicrobial Susceptibility Testing Market, by Type
- Antimicrobial Susceptibility Testing Market, by Application
- Antimicrobial Susceptibility Testing Market, by End-User
- Americas Antimicrobial Susceptibility Testing Market
- Asia-Pacific Antimicrobial Susceptibility Testing Market
- Europe, Middle East & Africa Antimicrobial Susceptibility Testing Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 26]
- List of Tables [Total: 562]
- List of Companies Mentioned [Total: 31]
Antimicrobial susceptibility testing (AST) is the cornerstone of modern medicine's battle against infectious diseases. It is a vital laboratory technique used to determine the effectiveness of antibiotics against specific microorganisms. The significance of AST lies in its ability to guide clinicians in selecting the most appropriate and effective treatment for infections, thereby minimizing the risk of resistance development and improving patient outcomes.
In recent years, AST has seen notable innovations transforming how to combat infections. One of these innovations is adopting automated systems, which offer quicker and more precise results that save time and reduce the potential for human error. In June 2023, Sysmex Corporation launched a testing system in Europe for rapid detection of antimicrobial susceptibility that detects the presence or absence of bacteria and assesses the effectiveness of antimicrobials.
Given the critical role of AST in guiding treatment decisions, regulations and standardization are essential. Several regulatory bodies, such as the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing, provide guidelines & breakpoints to ensure consistent and reliable testing procedures.
Innovations in technology and a focus on precision medicine are changing the landscape of AST, while regulations and standards are crucial to maintaining the quality and integrity of these tests.
The rise of antimicrobial resistance is one of the major concerns in the healthcare sector. The overuse and improper use of antibiotics have led to the development of antibiotic-resistant bacteria, causing difficulties in treating common infections. Hence, antimicrobial susceptibility testing is essential to know bacterial strains' resistance patterns and administer the appropriate antibiotic therapy. This test determines which drug or combination of drugs effectively treats the infection, reducing the risk of resistance.
The traditional method of antimicrobial susceptibility testing involved culturing the bacteria or virus in the lab and testing its response to antibiotics. This process took several days, making it difficult for clinicians to provide timely treatment. However, technological advancements in this field have led to the development of faster and more accurate testing methods. Automated systems analyze many samples simultaneously and provide results within a few hours. This reduces the turnaround time and makes it easier for clinicians to select the appropriate antibiotic therapy quickly.
Another advancement is the use of molecular diagnostic techniques for antimicrobial susceptibility testing. This method involves analyzing the bacterium's genetic material to identify the resistance genes. By knowing the presence of these genes, clinicians can predict which antibiotic may not work against the infection. This technique is faster, more accurate, and can detect resistance even in the initial stages of infection.
In addition to treating infections, antimicrobial susceptibility testing plays a crucial role in epidemiology. The resistance patterns of bacteria can help identify the emergence of new strains and track outbreaks. This information guides public health officials to implement corrective measures to prevent the spread of infections.
Antimicrobial susceptibility testing is an important diagnostic test in the age of technological advancements in disease diagnosis. It helps in administering effective antibiotic therapy, reducing the risk of resistance, and tracking outbreaks. Technological advancements have made this test faster and more accurate, enabling clinicians to provide timely patient treatment. With the increasing concern regarding the emergence of antibiotic-resistant bacteria, it is more important than ever to use this test to guide appropriate antibiotic therapy and prevent unnecessary use of antibiotics.
- How big is the Antimicrobial Susceptibility Testing Market?
- What is the Antimicrobial Susceptibility Testing Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?